ARPA-H announced THRIVE, a $160 million effort to accelerate custom gene-editing therapies into the clinic for rare genetic pediatric diseases. The program will fund seven teams using diverse approaches, with a stated goal of initiating clinical trials by year three for participating teams. The rollout signals a focused shift toward bespoke editing designs—where target biology is individualized—supported by federal funding intended to bridge preclinical execution, trial readiness, and early clinical conversion.